Patent details

EP1086076 Title: SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE

Basic Information

Publication number:
EP1086076
PCT Application Number:
PCT/US/1999/013744
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP999287691
PCT Publication Number:
WO/1999/065870
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE
French Title of Invention:
INHIBITEURS SULFONAMIDES D'ASPARTYLE PROTEASE
German Title of Invention:
SULFONAMIDE ALS ASPARTYL-PROTEASE-INHIBITOREN
SPC Number:

Dates

Filing date:
17/06/1999
Grant date:
22/12/2004
EP Publication Date:
22/12/2004
PCT Publication Date:
23/12/1999
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
28/03/2001
EP B1 Publication Date:
22/12/2004
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
17/06/2006
Expiration date:
17/06/2019
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
17/06/1999
 
 

Name:
VERTEX PHARMACEUTICALS INCORPORATED
Address:
130 Waverly Street, Cambridge, MA 02139-4242, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
02/03/2005
Address:
PO Box 48, 8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
ANDREWS Clarence W., III, Glaxo Wellcome Inc.
Address:
United States (US)

2

Name:
HALE Michael, R.
Address:
United States (US)

3

Name:
SPALTENSTEIN Andrew, Glaxo Wellcome Inc.
Address:
United States (US)

4

Name:
FURFINE Eric Steven, Glaxo Wellcome Inc.
Address:
United States (US)

5

Name:
LOWEN Gregory, Thomas
Address:
United States (US)

6

Name:
SHERRILL Ronald George, Glaxo Wellcome Inc.
Address:
United States (US)

Priority

Priority Number:
90094 P
Priority Date:
19/06/1998
Priority Country:
United States (US)

Classification

Main IPC Class:
C07C 303/00;
Filing date Document type Number of pages